Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Annovex Pharma, Inc
WARNING LETTER
•Annovex Pharma, Inc•September 6, 2024

Annovex Pharma, Inc – FDA Warning Letter, Sep 6, 2024

Record Details

On March 5, 2025, the FDA issued Warning Letter #698115 to Annovex Pharma, Inc., an outsourcing facility registered under section 503B of the FDCA. The letter followed an inspection from August 26 to September 6, 2024, which revealed serious deficiencies in drug production practices and failure to meet 503B conditions, putting patients at risk.

Violations included: - **Failure to meet 503B conditions:** Annovex Pharma failed to submit the June 2024 drug product report and did not submit adverse event reports according to 21 CFR 310.305 requirements, including inadequate procedures for defining, investigating, and reporting serious and unexpected adverse events. This renders their compounded drugs ineligible for exemptions from FDA approval, adequate directions for use labeling, and Drug Supply Chain Security Act requirements. - **Adulterated drug products:** Drug products were prepared under insanitary conditions, including media fills not performed under challenging conditions with uninvestigated positive growth, and inadequate smoke studies. This constitutes adulteration under section 501(a)(2)(A) of the FDCA. - **CGMP violations:** The facility failed to establish and follow procedures to prevent microbiological contamination (21 CFR 211.113(b)), thoroughly investigate discrepancies (21 CFR 211.19

Company
Annovex Pharma, Inc
Inspection date
September 6, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • F. Gail Bormel (F.)
View Company Profile

ID · 30d6a041-96ea-4490-ae01-8eba6a88126f

Violation Codes10
21 U.S.C. 353b21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 360eee-121 U.S.C. 353b(d)(4)21 U.S.C. 351(a)(2)(A)21 CFR 21021 CFR 21121 U.S.C. 331(k)21 U.S.C. 331(d)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Annovex Pharma, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.